Company intelligence / Profile preview

Pacific Diabetes Technologies

Portland, Oregon, United Statespacificdt.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Pacific Diabetes Technologies has developed SynerG™, the world’s first single-port device that combines continuous glucose monitoring and insulin infusion. The core technology has passed biocompatibility testing and been studied in humans. The company is preparing for its first FDA IDE submission to begin clinical trials, with a focus on building a commercial-ready design and pilot production plant.

Therapeutic areas: Endocrinology
Modalities: Device (continuous glucose monitoring and insulin infusion)Biologic (insulin, as delivered by the device)
Industry: Physiological Monitoring

Partnerships

Breakthrough T1D (formerly JDRF) – industry development/discovery partnership/funding support for product development

Beyond the preview

Go deeper on Pacific Diabetes Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pacific Diabetes Technologies.

Explore the full profile